Declines 'modest' due to current state of market
Jump in phishing and 'smishing' tactics reported
Ozan Kazim will report to Selina Tyler
Eye on large-cap pharma and biotech
Raft of portfolio management changes
UK firms face 'significant reputational ramifications'
Will be replaced by COO Ciaran Whelan